NADAC acquisition cost data for OXYMORPHONE HCL ER 40 MG TAB. This is a generic medication, typically more affordable than brand-name equivalents.
| NDC | NADAC/Unit | Effective Date | Type |
|---|---|---|---|
| 64896070101 | $18.32 | 2021-06-23 | Rx |
| 64896070113 | $18.32 | 2021-06-23 | Rx |
| 64896070101 | $18.32 | 2021-06-23 | Rx |
| 64896070113 | $18.32 | 2021-06-23 | Rx |
| 64896070101 | $18.32 | 2021-06-23 | Rx |
| 64896070113 | $18.32 | 2021-06-23 | Rx |
| 64896070101 | $18.32 | 2021-06-23 | Rx |
| 64896070113 | $18.32 | 2021-06-23 | Rx |
| 64896070101 | $18.32 | 2021-06-23 | Rx |
| 64896070113 | $18.32 | 2021-06-23 | Rx |
Generic: Oxymorphone HCl | Manufacturer: Overall
| Year | Total Spending | Claims | Beneficiaries | Cost/Unit |
|---|---|---|---|---|
| 2019 | $5.3M | 32,038 | 4,808 | $1.64 |
| 2020 | $3.9M | 28,140 | 3,533 | $1.38 |
| 2021 | $4.0M | 24,480 | 3,070 | $1.64 |
| 2022 | $3.3M | 20,433 | 2,638 | $1.65 |
| 2023 | $851.2K | 6,008 | 1,477 | $1.61 |
The DrugPricePeek editorial team aggregates and verifies drugs data from CMS NADAC & Medicare Part D. Every statistic on this site is cross-referenced against the official source before publication, with quarterly re-verification cycles.
Read our full methodology or contact us with corrections.
Explore More Data Tools
For adjacent public-data tools, methodology notes, and network updates, visit DataPeek Facts.